BSI-001
/ Biosion, Anhui Anke Biotech
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 09, 2022
BSI-001, a novel anti-HER2 antibody exhibiting potent synergistic efficacy with trastuzumab
(AACR 2022)
- "BSI-001 is the best functional partner of trastuzumab identified through the SynAbTM platform. BSI-001 binds to a unique epitope, distinct from the binding epitopes of trastuzumab and pertuzumab. It exhibits superior bioactivity and efficacy in vitro and in vivo when combined with trastuzumab."
Clinical • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1